Evidence map›Paper›PMID 39431736›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2024

Synthesis and biological evaluation of quinoxaline derivatives as ASK1 inhibitors.

Xiaorui Han, Pingping Lan, Qianfeng Chen, Hua Liu, Zhongwen Chen, Tiantian Wang, Zengtao Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Chemistry and Biological Activity of 11Molecules (Basel, Switzerland) · 2026
    Review
  2. NovelMolecules (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaorui HanJiangxi Provincial Key Laboratory of TCM Female Reproductive Health and Related Diseases Research and Transformation, Jiangxi University of Chinese Medicine, Nanchang, PR China.
Pingping LanCollege of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, PR China.
Qianfeng ChenCollege of Chinese Medicine and Life Science, Jiangxi University of Chinese Medicine, Nanchang, PR China.
Hua LiuCollege of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, PR China.
Zhongwen ChenCollege of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, PR China.
Tiantian WangNational Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang, PR China.
Zengtao WangJiangxi Provincial Key Laboratory of TCM Female Reproductive Health and Related Diseases Research and Transformation, Jiangxi University of Chinese Medicine, Nanchang, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibiting apoptosis signal regulated kinase 1 (ASK1) is an attractive strategy for treating diseases such as non-alcoholic steatohepatitis and multiple sclerosis. Here, we report the discovery of a dibromo substituted quinoxaline fragment containing

Indexed as

Dose-Response Relationship, DrugMAP Kinase Kinase Kinase 5Protein Kinase InhibitorsQuinoxalinesCell LineCell SurvivalHumansMolecular StructureStructure-Activity RelationshipMAP3K5 protein, humanMAP Kinase Kinase Kinase 5Protein Kinase InhibitorsQuinoxalinesASK1 inhibitorsbiological evaluationquinoxaline derivativesSynthesis

Identifiers

PMID39431736
PMCPMC11494716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.